USSN 10/758,155 MBHB02-742-N (400/141)

**REMARKS** 

The title of the application has been amended to more accurately reflect the claimed subject

matter.

In response to the Restriction Requirement mailed on October 27, 2005, Applicants hereby

submit claim amendments which render the restriction requirement moot. Specifically, Applicants

have amended the claims to be drawn to a double-stranded nucleic acid molecule having an

antisense strand that is complementary to nucleic acid sequence encoding vascular endothelial

growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 2 (VEGFR2) or

a portion thereof. The present claims are meant to cover, for example, double-stranded nucleic acid

molecule having an antisense strand that is complementary to nucleic acid sequence that is present in

mRNAs encoding vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial

growth factor receptor 2 (VEGFR2), respectively. Therefore the antisense strand of a single double

stranded nucleic acid molecule has sequence complementary to two separate mRNAs, one encoding

VEGFR1 and the other encoding VEGFR2.

Support for the amendments can be found throughout the specification (for example, page

12) and in the original claims. Thus, no new matter has been added by way of the amendments.

Claims 4-9, 25-31, and 33-34 have been canceled. Amendments to the claims are made

without prejudice and do not constitute amendments to overcome any prior art or other statutory

rejections. Additionally, these amendments are not an admission regarding the patentability of

subject matter of the canceled or amended claims and should not be so construed. Applicant reserves

the right to pursue the subject matter of the previously filed claims in this or in any other appropriate

patent application.

Date: November 28, 2005

Respectfully submitted,

nita J. Terpstra

Registration No. 47,132

McDonnell Boehnen Hulbert & Berghoff, LLP 300 South Wacker Drive, 32nd Floor Chicago, Illinois 60606

Phone: 312-913-0001

Fax: 312-913-0002

6